Anthony Pinkerton - Boundless Bio, Senior Discovery
| BOLD Stock | USD 2.52 0.14 5.26% |
Executive
Anthony Pinkerton is Senior Discovery of Boundless Bio, Common
| Address | 9880 Campus Point Drive, San Diego, CA, United States, 92121 |
| Phone | 858 766 9912 |
| Web | https://boundlessbio.com |
Boundless Bio, Management Efficiency
The company has return on total asset (ROA) of (0.2369) % which means that it has lost $0.2369 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3574) %, meaning that it created substantial loss on money invested by shareholders. Boundless Bio,'s management efficiency ratios could be used to measure how well Boundless Bio, manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 0.41, whereas Return On Tangible Assets are forecasted to decline to (0.40). At present, Boundless Bio,'s Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.03, whereas Non Currrent Assets Other are forecasted to decline to about 527.2 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Ganesh Pattabiraman | NextNav Warrant | 50 | |
| Jake Fuellhart | LB Foster | N/A | |
| James Bogdan | LB Foster | N/A | |
| Brian Cuppett | ScanSource | N/A | |
| Alexandre Conde | ScanSource | N/A | |
| Chantal LLB | TFI International | N/A | |
| Carol Sharkey | Ryanair Holdings PLC | 48 | |
| Stephanie Listwak | LB Foster | N/A | |
| Robert Farbak | ScanSource | N/A | |
| Brian Friedman | LB Foster | 45 | |
| Michal Kaczmarzyk | Ryanair Holdings PLC | 44 | |
| Juliusz Komorek | Ryanair Holdings PLC | 46 | |
| Rick Hashie | TFI International | N/A | |
| Gillian Smith | NextNav Warrant | N/A | |
| Sean CPA | LB Foster | 51 | |
| Sammaad Shams | NextNav Warrant | N/A | |
| JinAn Lee | Amkor Technology | N/A | |
| Christian Gates | NextNav Warrant | 50 | |
| Jennifer Jue | Amkor Technology | N/A | |
| Robert Lantz | NextNav Warrant | 61 | |
| Jason Weidman | ScanSource | N/A | |
Management Performance
| Return On Equity | -0.36 | ||||
| Return On Asset | -0.24 |
Boundless Bio, Common Leadership Team
Elected by the shareholders, the Boundless Bio,'s board of directors comprises two types of representatives: Boundless Bio, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Boundless. The board's role is to monitor Boundless Bio,'s management team and ensure that shareholders' interests are well served. Boundless Bio,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Boundless Bio,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christian Hassig, Chief Officer | ||
| MS MBA, Chief Officer | ||
| Jessica JD, Chief Secretary | ||
| Jamilu Rubin, Chief Officer | ||
| Meredith Wesley, Senior Culture | ||
| Zachary Hornby, President CEO | ||
| David Hinkle, Senior Controller | ||
| Shailaja Kasibhatla, Senior Development | ||
| Peter Krein, Senior Medicine | ||
| Anthony Pinkerton, Senior Discovery | ||
| Jonathan MD, CoFounder Chairman |
Boundless Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Boundless Bio, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.36 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | (98.56 M) | ||||
| Shares Outstanding | 22.25 M | ||||
| Shares Owned By Insiders | 11.46 % | ||||
| Shares Owned By Institutions | 78.60 % | ||||
| Number Of Shares Shorted | 212.5 K | ||||
| Price To Earning | (7.22) X | ||||
| Price To Book | 0.45 X | ||||
| EBITDA | (48.48 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Boundless Bio, Common is a strong investment it is important to analyze Boundless Bio,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Boundless Bio,'s future performance. For an informed investment choice regarding Boundless Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boundless Bio, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Boundless Bio,. If investors know Boundless will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Boundless Bio, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.59) | Return On Assets (0.24) | Return On Equity (0.36) |
The market value of Boundless Bio, Common is measured differently than its book value, which is the value of Boundless that is recorded on the company's balance sheet. Investors also form their own opinion of Boundless Bio,'s value that differs from its market value or its book value, called intrinsic value, which is Boundless Bio,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Boundless Bio,'s market value can be influenced by many factors that don't directly affect Boundless Bio,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Boundless Bio,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Boundless Bio, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Boundless Bio,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.